{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gregory GP"],"funding":["NCI NIH HHS"],"pagination":["1232-1242"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8864641"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(4)"],"pubmed_abstract":["Preclinical data demonstrated that combining an anti-programmed cell death 1 (PD-1) inhibitor with a cyclin-dependent kinase 9 (CDK9) inhibitor provided enhanced antitumor activity with no significant toxicities, suggesting this combination may be a potential therapeutic option. The multicohort, phase 1 KEYNOTE-155 study evaluated the safety and antitumor activity of the PD-1 inhibitor pembrolizumab plus the CDK9 inhibitor dinaciclib in patients with relapsed or refractory (rr) chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM). Patients enrolled were ≥18 years of age with a confirmed diagnosis of CLL, DLBCL, or MM. The study included 2 phases: a dose-evaluation phase to determine dose-limiting toxicities and a signal-detection phase. Patien"],"journal":["Blood advances"],"pubmed_title":["Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study."],"pmcid":["PMC8864641"],"funding_grant_id":["P30 CA015083"],"pubmed_authors":["Bannerji R","Escobar C","Marinello P","Wang D","Walker P","Mahadevan D","Huang M","Yee AJ","Mohrbacher A","Farooqui M","Kumar S","Bhutani D","Quach H","Klein A","Gregory GP","Pagel JM","Rybka W","Chang J","Hernandez-Ilizaliturri FJ","Wagner-Johnston N"],"additional_accession":[]},"is_claimable":false,"name":"Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study.","description":"Preclinical data demonstrated that combining an anti-programmed cell death 1 (PD-1) inhibitor with a cyclin-dependent kinase 9 (CDK9) inhibitor provided enhanced antitumor activity with no significant toxicities, suggesting this combination may be a potential therapeutic option. The multicohort, phase 1 KEYNOTE-155 study evaluated the safety and antitumor activity of the PD-1 inhibitor pembrolizumab plus the CDK9 inhibitor dinaciclib in patients with relapsed or refractory (rr) chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM). Patients enrolled were ≥18 years of age with a confirmed diagnosis of CLL, DLBCL, or MM. The study included 2 phases: a dose-evaluation phase to determine dose-limiting toxicities and a signal-detection phase. Patien","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2026-05-30T23:53:49.603Z","creation":"2025-04-05T15:03:25.836Z"},"accession":"S-EPMC8864641","cross_references":{"pubmed":["34972202"],"doi":["10.1182/bloodadvances.2021005872"]}}